Synthetic Corticotropin Therapy Reduces Microglial Activation in a Rodent TBI Model

Abstract

Traumatic brain injury (TBI) is a leading cause of mortality/morbidity and is associated with chronic neuroinflammation. Melanocortin receptor (MCR) agonists (e.g., ACTH or adrenocorticotropic hormone) that target MC3R/4R ameliorate inflammation and provide a novel therapeutic approach. Following TBI, quiescent microglia become activated resulting in anti and pro‐inflammatory responses and morphological changes. We examined the effect of Cosyntropin (synthetic ACTH) administration on microglial activation through quantification of microglia morphology in a rodent TBI model. We hypothesized that Cosyntropin administration would reduce injury‐induced microglia morphological changes following experimental TBI in rats. We used CCI in adult Sprague‐Dawley rats, randomized to 4 groups: sham‐vehicle (N = 2), sham‐Cosyntropin (N = 2), CCI‐vehicle (N = 4), and CCI‐Cosyntropin (N = 4). Subcutaneous injections of Cosyntropin (120U/kg/day; West Therapeutic Development; Grayslake, IL) were given 30 minutes after CCI and every 12 hours for 7 days thereafter. Microglia activation was quantified based on morphology. Sectioned brains were immunostained (Iba1) and visualized with diaminobenzidine. Image processing and quantification were conducted with FIJI and FracLac for ImageJ resulting in 15 morphological values/cell. Parameters included cell area, fractal dimension, circularity, and cell perimeter and density. CCI animals exhibited increased microglia in the lesion site with no difference in cell count between vehicle and treated. Microglia from CCI animals exhibited no change in cell area, decreased cell perimeter and increased density and circularity compared to sham animals. Cosyntropin treatment altered CCI‐induced microglia changes in cell area, cell perimeter, and cell density. Cosyntropin‐treated CCI animals showed reduced morphological changes in microglia suggesting a reduced activation state. Decreased activation may decrease long‐term deleterious neuroinflammatory effects and may be mediated by Cosyntropin effects on melanocortin receptor signaling.Support or Funding InformationSupported in part by the Pediatric Epilepsy Research Foundation. Cosyntropin was supplied by West Therapeutic Development (Grayslake, IL).This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.